Barely Significant
← all excerpts

Laquinimod therapy in multiple sclerosis: a comprehensive review.

Neurol Ther · 2014 · PMC4381916 · PMID 26000222

Europe PMCDOI
2
hedged sentences
0.0750
closest p · 1.5× alpha
0.0750
boldest claim

The sentences

showed a trendP = 0.075so close (0.05 < p ≤ 0.1)
The primary endpoint was the ARR which did not reach statistical significance, but showed a trend to reduction with laquinimod [Risk ratio (RR) = 0.823, 95% CI 0.664–1.020; P = 0.075].

also in 53,322 other papers

did not reach statistical significanceno p-value reported
Annualized relapse rate (ARR) also decreased in the 0.6 mg/day treatment group by 32% but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.